Bamlanivimab is a neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19. Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.
- Mechanism
- Curator reviewed · 4 references
Bamlanivimab is a neutralizing recombinant human IgG1κ monoclonal antibody directed against the spike (S) surface protein of SARS-CoV-2 derived from screening antigen-specific B-cells from a convalescent COVID-19 patient. X-ray crystallography and cryo-EM structural determination suggest that bamlanivimab binds the receptor-binding domain (RBD) of the S protein at a position overlapping the ACE2 binding site and which is accessible in both the up and down conformations of the RBD. Specifically, bamlanivimab binds to the S protein with a KD of 0.071 nM and blocks S protein-ACE2 interactions with an IC50 value of 0.025 μg/mL.
- Primary indication
- Bamlanivimab is not currently approved for any indication by the FDA.Curator reviewed · 3 structured indications
- Formula / weight
- C6498H10068N1732O2032S46 · 146000.0 Da
- First approval
- Canada, 2020
- Code names
- LY-3819253 · LY-CoV555
Resolves to
What you can answer from here — as of March 03, 2026
Which drugs share a target with Bamlanivimab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account